Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.

Abstract

The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will… (More)
DOI: 10.3816/CLM.2008.s.003

Topics

Cite this paper

@article{QuintsCardama2008PracticalMO, title={Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.}, author={Alfonso Quint{\'a}s-Cardama and Jorge E. Cortes and Hagop M. Kantarjian}, journal={Clinical lymphoma & myeloma}, year={2008}, volume={8 Suppl 3}, pages={S82-8} }